Overview

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

Primary Objective: - To compare the continuation of treatment with docetaxel versus switching to cabazitaxel regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in patients with Castration-Resistant Prostate Cancer (CRPC) that, after four cycles of docetaxel, have minor PSA response (defined as a reduction between 1% and 49%) or increase of up to 24% in PSA levels. Secondary Objectives: - PSA response rate - Overall survival (OS) - Incidence of Adverse Events

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Docetaxel